An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent

Trial Profile

An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 02 Aug 2017 Planned number of patients changed from 2000 to 400.
    • 06 Dec 2016 Results assessing effect of Montelukast use on infusion related reactions presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 25 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top